Article
Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Endocrinology - 1 Feb 2015
Matsushita Masaki, Hasegawa Satoru, Kitoh Hiroshi, Mori Kensaku, Ohkawara Bisei, Yasoda Akihiro, Masuda Akio, Ishiguro Naoki, Ohno Kinji
Abstract excerpt
Achondroplasia (ACH) is one of the most common skeletal dysplasias causing short stature owing to a gain-of-function mutation in the FGFR3 gene, which encodes the fibroblast growth factor receptor 3. We found that meclozine, an over-the-counter drug for motion sickness, inhibited elevated FGFR3 signaling in chondrocytic cells. To examine the feasibility of meclozine administration in clinical settings, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.